According to the guidelines of the European Association for the Study of Liver (EASL), patients affected from hepatocellular carcinoma (HCC) can be classified according to the Barcelona Clínic Liver Cancer (BCLC) staging system. This classification system divides HCC patients in 5 stages (0, A, B, C and D) on the basis of a number of prognostic and treatment-related variables such as tumor status and liver function. A specific treatment approach is then proposed for each of the above-mentioned stages.
